What Is Maternal Serum and What Does It Screen For?

Maternal serum is simply a pregnant person’s blood, specifically the liquid portion after cells and clotting factors are removed. During pregnancy, the placenta releases proteins and hormones into this blood, and measuring those substances gives doctors a way to estimate the risk that a fetus has certain chromosomal conditions or structural problems. The screening typically targets Down syndrome, Edwards syndrome, Patau syndrome, and neural tube defects, though the same blood markers can also flag risks for complications like preeclampsia and fetal growth restriction. The tests are screening tools, not diagnoses, and understanding that distinction matters for everything that follows.

What the Placenta Puts Into Your Blood

Once a placenta is established, it functions as a two-way interface between you and the fetus. But the exchange is not symmetrical. A proteomic study sampling blood from both sides of the placenta found that 34 proteins were significantly secreted into the maternal circulation, while only 7 of those same proteins also crossed into the fetal side.¹ The placenta, in other words, is actively pushing a specific set of molecules into your bloodstream. Some of those molecules, like pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG), shift in predictable ways when a fetus has a chromosomal abnormality. That predictability is what makes serum screening possible: measure the right proteins at the right time, and you get meaningful information about risk.

First Trimester Screening

The earliest serum-based screen is usually offered between about 11 and 14 weeks. It combines two blood markers with an ultrasound measurement. The blood markers are PAPP-A and the free beta subunit of hCG. The ultrasound measurement is nuchal translucency, the fluid-filled space at the back of the fetal neck. When all three are combined with your age, the result is a single risk estimate for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).²

Each condition leaves a different fingerprint on these markers. All three trisomies tend to show decreased PAPP-A and increased nuchal translucency. But hCG diverges: in Down syndrome it rises, while in Edwards and Patau syndromes it falls.² That pattern of divergence is what lets the algorithm distinguish among the three conditions rather than lumping them together.

How well does this work? An early modeling study found that using serum biochemistry alone detected about 61% of Down syndrome cases at a 5% false-positive rate, nuchal translucency alone detected about 73%, and combining both methods pushed detection to roughly 87%.³ A cost-effectiveness analysis comparing the combined screen to the older second-trimester AFP-based screen found that the combined first-trimester approach identified substantially more affected pregnancies.⁴ That improvement over the older approach is one reason first-trimester screening became standard practice.

Second Trimester Screening and the Quad Test

If you enter prenatal care later or want additional information, a second-trimester blood draw between about 15 and 22 weeks measures a different set of markers. The quad test includes alpha-fetoprotein (AFP), hCG, unconjugated estriol (uE3), and inhibin A. Together with maternal age, these produce risk estimates for Down syndrome, Edwards syndrome, and open neural tube defects.

Each marker carries different information. AFP is produced by the fetal liver and normally present in maternal blood at low levels; unusually high AFP suggests a neural tube defect or abdominal wall defect, while unusually low AFP is associated with Down syndrome. Unconjugated estriol reflects placental function and tends to drop in affected pregnancies. Inhibin A rounds out the picture by adding information about placental hormone output. A population-based study found that high AFP, high hCG, and high inhibin A but low estriol also increased the risk of a baby being born small for gestational age, suggesting these markers capture more than just chromosomal risk.⁵

Neural Tube Defect Screening

Screening for neural tube defects like spina bifida and anencephaly was actually the original purpose of maternal serum screening. Measuring AFP in the second trimester was considered the gold standard for about four decades.⁶ The logic is straightforward: when the fetal spine or skull is not fully closed, fetal AFP leaks into the amniotic fluid and then into your blood at higher-than-expected levels.

In recent years, high-resolution ultrasound has largely replaced AFP as the primary way to detect neural tube defects, since it can directly visualize the anatomy rather than relying on an indirect marker.⁶ But AFP measurement persists as part of the quad screen, where it pulls double duty: screening for neural tube defects at the high end of the range and contributing to chromosomal risk assessment at the low end. You might hear providers talk about MSAFP as though it were a separate test; it is just the AFP component of the broader screen, sometimes ordered on its own.

How Screening Strategies Combine Trimesters

One of the more confusing aspects of maternal serum screening is the number of different protocols that combine first- and second-trimester results in different ways. The three main approaches are integrated, sequential, and contingent screening. They use the same underlying markers but differ in when you get results and whether you need the second blood draw at all.

Integrated screening collects first-trimester markers and withholds results until second-trimester markers are also available, then calculates a single combined risk. This approach produced an 85% detection rate for Down syndrome with a false-positive rate of just 0.9%, compared to a 69% detection rate for the older triple test at a 5% false-positive rate.⁷ The tradeoff is that you wait weeks for any result at all, which can be stressful.

Sequential screening gives you the first-trimester result right away. If the risk is very high, you can proceed directly to diagnostic testing without waiting for the second trimester. If not, second-trimester markers refine the risk. Contingent screening works similarly but adds a middle category: if your first-trimester risk is very low, you are done and skip the second draw entirely. A study of over 7,000 high-risk pregnancies found that the contingent approach achieved the same final detection rates as the integrated test but with a lower false-positive rate (about 2.6%) and only required about 13% of women to come back for second-trimester testing.⁸ A separate simulation analysis confirmed that contingent screening allowed roughly 78% of women to be reassured with a negative result in the first trimester.⁹

Which protocol your provider uses depends on local resources, when you first present for care, and how your health system balances detection rates against the number of follow-up procedures. None of these approaches is universally “best”; the differences are in the tradeoffs among detection, false positives, timing of results, and cost.

What Abnormal Markers Can Tell You Beyond Chromosomes

Researchers have known for years that the same serum markers used for aneuploidy screening carry information about pregnancy complications unrelated to chromosomal conditions. Abnormal levels of first- or second-trimester markers have been linked to adverse outcomes including fetal growth restriction, preeclampsia, preterm birth, and stillbirth.¹⁰ The connection makes biological sense: many of these markers reflect how well the placenta is functioning, and a poorly functioning placenta underlies both growth restriction and conditions like preeclampsia.

A study focused on severe growth restriction with abnormal umbilical blood flow found that extreme values of several routine markers were dramatically more common in affected pregnancies. Very low PAPP-A, very high inhibin A, very high AFP, and very low estriol each carried substantially elevated odds of this outcome, and when multiple markers were abnormal simultaneously, the combination detected about 73% of the most severely affected fetuses.¹¹ First-trimester PAPP-A levels combined with a second-trimester ultrasound measure of uterine artery blood flow have also been shown to improve screening for both preeclampsia and fetal growth restriction.¹²

First-trimester markers have also been studied for their ability to predict growth restriction on their own. Low PAPP-A, high free beta-hCG, and low nuchal translucency were all associated with fetal growth restriction in one large retrospective study, though the authors cautioned that none of the markers individually performed well enough to serve as a standalone predictor.¹³ The practical upside is that if your serum screen comes back with unexplained abnormalities but the fetus is chromosomally normal, your provider may increase surveillance for complications later in pregnancy.

Factors That Shift Your Numbers

Serum marker levels are not just about the fetus. Your own body influences the results, and screening programs have to adjust for that. Marker concentrations are affected by factors such as race, smoking status, insulin-dependent diabetes, and whether the pregnancy was conceived through IVF. Accurate risk estimation requires adjusting the raw numbers for these characteristics.¹⁴

Gestational dating is another major variable. Because marker levels change significantly week by week, even a one- or two-week error in how far along you are can shift the calculated risk in the wrong direction. Screening programs require precise dating, usually confirmed by ultrasound, to keep risk assessment accurate.¹⁵

Maternal weight also matters because a larger blood volume dilutes the markers. And metabolic factors like obesity and excess gestational weight gain are associated with changes in inflammatory and metabolic biomarkers, including insulin and leptin, which can further complicate interpretation.¹⁶ Labs apply mathematical correction factors for these variables before generating your risk number, but the corrections are not perfect, which is one reason screening sometimes gives false results.

Twin pregnancies add another layer of complexity. Two placentas (or one shared placenta) produce roughly double the amount of serum markers. Screening programs adjust for this using correction factors specific to the type of twin pregnancy, though detection rates for twins are generally lower and false-positive rates higher than for singletons.¹⁷

Screening Versus Diagnosis

The single most important thing to understand about maternal serum screening is that a “positive” or “high-risk” result does not mean your baby has a condition. It means the estimated risk crossed a threshold that warrants further investigation. The vast majority of people who screen positive end up having an unaffected pregnancy. A false-positive result can cause genuine distress: one prospective study found that women who received an initial positive AFP result experienced elevated anxiety, more worry about the baby’s health, and a more negative attitude toward the pregnancy compared to women who screened negative, and those effects persisted into the postpartum period.¹⁸

A positive serum screen is typically followed by either cell-free DNA testing (often called NIPT), a detailed ultrasound, or a diagnostic procedure. The definitive diagnostic tests are chorionic villus sampling (CVS) in the first trimester and amniocentesis in the second. Both involve obtaining fetal cells and analyzing the chromosomes directly. In a recent study of pregnancies referred after high-risk NIPT results, about 70% underwent CVS and 30% had amniocentesis.¹⁹ These procedures carry a small risk of miscarriage, which is why screening exists as a first step: it narrows the pool of people who need an invasive test.

How Cell-Free DNA Testing Fits In

Over the past decade, cell-free DNA screening (NIPT) has transformed prenatal screening. This test analyzes fragments of placental DNA floating in your blood and can estimate the risk of trisomies 21, 18, and 13 with higher sensitivity and a much lower false-positive rate than traditional serum screening. In many settings, it has become the primary screen for chromosomal conditions, especially for pregnancies already identified as higher risk.

But NIPT has not made traditional serum screening obsolete. For one thing, NIPT is more expensive. A large real-world cost-effectiveness analysis of over 140,000 women found that universal NIPT was the most effective strategy, catching the most cases, but contingent approaches where serum screening was used first and NIPT was reserved for intermediate-risk results offered a better balance of effectiveness and cost.²⁰ A separate analysis modeling screening strategies for developing countries also found that using NIPT as a secondary screen after initial serum screening was the most cost-beneficial approach.²¹

There is also the point that traditional serum markers detect things NIPT cannot. NIPT looks at chromosomes; it does not measure AFP or other markers linked to neural tube defects, growth restriction, or preeclampsia risk. So even in systems that lead with NIPT for chromosomal screening, serum markers may still be drawn for their information about other pregnancy complications.

The Evolution From One Marker to Many

Prenatal screening has changed dramatically in a relatively short time. The very first serum screen was a single marker, AFP, used to flag neural tube defects.²² Before that, the only way to estimate chromosomal risk was maternal age alone, which is a blunt instrument. The shift to combined first-trimester screening using multiple serum and ultrasound markers, and eventually to circulating cell-free fetal DNA, represents about three decades of iterative improvement.²³

Researchers are now looking at whether large-scale molecular analyses of maternal plasma could identify biomarkers for congenital malformations that current screening misses entirely, including heart defects and other structural anomalies.²⁴ The long-term trajectory is toward screening that captures more conditions, earlier, from a simple blood draw.

Informed Consent and What You Should Know Before Saying Yes

Maternal serum screening is voluntary. You can decline it. But research has repeatedly found gaps between what providers assume patients understand and what patients actually grasp about the test. A study of an inner-city population found that women understood screening was voluntary but had poor comprehension of what a positive result actually meant or what would follow from it.²⁵ Comprehensive genetic counseling has been shown to improve pregnant women’s ability to make an autonomous decision about whether to participate.²⁶

A more recent ethics analysis argues that the current model, which front-loads extensive information before screening, may be misallocating resources. Most patients actively avoid deep moral deliberation before a test that will almost certainly come back negative, but families who do get a positive result frequently report minimal support afterward, leading to long-term distress. The proposed alternative is “just-in-time consent,” which provides essential information upfront but redirects the heavier counseling to the point when a family actually needs it, after a positive result.²⁷ Whatever the approach, the core principle is the same: you deserve to know what the test can and cannot tell you, what a positive result would mean, and what your options would be at each step.

When Screening Gets Complicated by Unexpected Findings

Sometimes serum screening produces results that do not fit neatly into the “high risk” or “low risk” buckets the test was designed for. Marker levels may be mildly abnormal in a pattern that does not clearly match any trisomy. This can happen when the fetus is chromosomally normal but the placenta is underperforming. In those cases, the abnormal markers function as an early warning of placental dysfunction rather than a chromosomal signal.

There is no standardized protocol for what to do with these ambiguous findings. Some providers will order additional ultrasound surveillance in the third trimester, monitoring fetal growth and amniotic fluid. Others may add uterine artery Doppler studies to assess blood flow to the placenta. The clinical guidance is still catching up with the evidence that routine screening markers carry meaningful prognostic information beyond aneuploidy, and how aggressively to act on mildly abnormal results remains a judgment call.

For you as a patient, the practical takeaway is worth knowing: if your screening results come back “normal” for chromosomal conditions but with one or more markers flagged as mildly out of range, it does not mean nothing. Ask your provider whether the specific pattern warrants any change in how the rest of your pregnancy will be monitored. The answer may be no, but the question is worth asking.